查詢結果分析
來源資料
相關文獻
- 對乳癌有關抗原具專一性之單株抗體的發展現況
- Ado-trastuzumab Emtansine:第一個用於固態腫瘤之抗體結合藥品
- 細胞表皮生長因子受體與乳癌標靶治療
- The Effects of Pesticides Chlordane, Dieldrin and Endosulfan on the Growth of Human Breast Cancer Cell Lines MCF-7 and SK-BR-3
- Prognostic Factors in Node-Negative Breast Cancer Patients: The Experience in Taiwan
- The Anti-Inflammatory Effect of a Long-Acting Theophylline (Unidur) in Patients with Bronchial Asthma
- Cystic Hypersecretory Intraductal Carcinoma of the Breast--Case Report
- Timing of Shoulder Exercise after Modified Radical Mastectomy: A Prospective Study
- 前哨淋巴掃描診斷乳癌早期轉移
- Measurement of the Quality of Life during Different Clinical Phases of Breast Cancer
頁籤選單縮合
題 名 | 對乳癌有關抗原具專一性之單株抗體的發展現況=Monoclonal Antibodies Specific to Breast Cancer-Associated Antigens |
---|---|
作 者 | 賴福明; 徐漢業; 林有啟; 孟慶樑; 劉鴻文; | 書刊名 | 醫學研究 |
卷 期 | 16:5 1996.03[民85.03] |
頁 次 | 頁285-294 |
分類號 | 416.226 |
關鍵詞 | 乳癌; 單株抗體; 腫瘤標幟; Breast cancer; Monoclonal antibody; Tumor marker; |
語 文 | 中文(Chinese) |
中文摘要 | 歐美許多國家中,乳癌(breast cancer)的死亡率一直是婦女癌症的第一位。我國乳癌的發生率是婦癌的第二位,而死亡率是婦癌的第四位;其發生率與死亡率並沒有逐年提升的情形,因此有關乳癌診斷及治療的研究,在臨床上具有重大之意義。抗乳癌單株抗體在乳癌的診斷及治療上深具潛力;目前學者已應用乳癌細胞膜粹取物(B72.3)、乳癌細胞株(MBR1)及雌性素受體(D547 Spr, D75P3r)等為免疫原製成單株抗體;但這些抗體目前還無法直接用來診斷乳癌。而單株抗體B-14乃本學院孟慶樑教授,以乳癌細胞株BC-M1的細胞膜粹取蛋白為免疫原所製備的單株抗體。本實驗室以此單株抗體B-14於乳癌的組織中,偵測到一分子量約為62kd的蛋白質;由於該抗原含有甘露糖(mannose)、唾液酸(sialic acid)及N-乙醯胺基葡萄糖(N-acetyl-glucosamine)等單醣類,因此命名為GP-62。目前正探討其臨床上的可能應用。 |
英文摘要 | Breast carcinoma is one of major malignancy among the female in many countries. Monoclonal antibodies specific to breast tumor-associated antigens are invaluable for early diagnosis and follow-up. Many monoclonal antibodies had been generated for this purpose with various antigens, e.g., membrane extracts of metastatic breast carcinoma (B72.3), breast carcinoma cell line (MBR1) or estrogen receptor (D547 Spr and D75P3r). The application of these antibodies in clinical diagnosis are being evaluated, and the roles of these antigens in the carcinogenesis of breast carcinoma are being investigated. A monoclonal antibody, B-14 is generated through the cell fusion of myeloma cells with spleen cells immunized with BCM-1, a breast carcinoma cell line. Immunoblots of BCM-1 cell extracts revealed a glycoprotein of 62 Kd. |
本系統中英文摘要資訊取自各篇刊載內容。